≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Thromboangiitis obliterans

DOID EFO Endpoint Browser PheWeb

I9_THROMBANG

thromboangiitis obliterans: Buerger disease, also known as thromboangiitis obliterans (TAO), is a rare inflammatory non-necrotizing vascular disease affecting the small- and medium-sized arteries and veins of the upper and lower extremities characterized by endarteritis and vaso-occlusion due to occlusive thrombus development. The development and progression of the disease is consistently associated with exposure to tobacco.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — I73.1
  • Hospital discharge: ICD-9 — 4431A
  • Hospital discharge: ICD-8 — 44310
  • Cause of death: ICD-10 — I73.1
  • Cause of death: ICD-9 — 4431A
  • Cause of death: ICD-8 — 44310

2 out of 7 registries used, show all original rules.

136

4. Check minimum number of events

None

136

5. Include endpoints

None

136

6. Filter based on genotype QC (FinnGen only)

135

Control definitions (FinnGen only)

Control exclude
I9_DOAAC

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
I73
Name in latin
Tromboangi(i)tis obliterans (Bürger)

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1319 389 900
Only index persons 869 322 547
Unadjusted period prevalence (%)
Whole population 0.02 0.01 0.03
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population 52.80 53.06 52.44
Only index persons 51.00 51.70 50.59

-FinnGen-

Key figures

All Female Male
Number of individuals 135 49 86
Unadjusted period prevalence (%) 0.03 0.02 0.04
Median age at first event (years) 49.50 46.58 51.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
136
Matched controls
1360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I73.1
ICD-10 Finland
Thromboangiitis obliterans [Buerger]
+∞
118.8
96
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
136.1
60.2
61
8
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
21.3
41.5
34
21
44310
ICD-8 Finland
Other peripheral vascular disease, Thrombo-angiitis obliterans (Buerger's disease)
+∞
36.1
33
*
C08CA05
ATC
nifedipine; systemic
10.0
27.8
37
49
4431A
ICD-9 Finland
Other peripheral vascular disease, Thromboangiitis obliterans [Buerger's disease]
+∞
24.7
23
*
4402A
ICD-9 Finland
Atherosclerosis, Of native arteries of the extremities
+∞
14.9
14
*
I71.4
ICD-10 Finland
Abdominal aortic aneurysm, without mention of rupture
130.6
11.6
12
*
I73.0
ICD-10 Finland
Raynaud syndrome
47.5
11.1
13
*
2424
FHL
Sympatectomy, lumbar
+∞
10.5
10
*
C08CA02
ATC
felodipine; oral
4.4
10.1
29
79
PD4BC
NOMESCO Finland
Extensive arterigography of lower extremity with X-ray
+∞
9.5
9
*
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
10.6
9.1
17
18
PD4AC
NOMESCO Finland
Arterigography of lower extremity with X-ray
53.5
8.8
10
*
I73.9
ICD-10 Finland
Peripheral vascular disease, unspecified
53.5
8.8
10
*
I73.8
ICD-10 Finland
Other specified peripheral vascular diseases
+∞
8.4
8
*
I71.3
ICD-10 Finland
Abdominal aortic aneurysm, ruptured
+∞
8.4
8
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
12.8
8.3
14
12
I70.9
ICD-10 Finland
Generalized and unspecified atherosclerosis
84.5
7.5
8
*
J01FF01
ATC
clindamycin; systemic
2.8
7.4
50
232
2423
FHL
Sympatectomy, thoracic
+∞
7.4
7
*
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
+∞
7.4
7
*
9571
FHL
Amputation of toe or toes
+∞
7.4
7
*
PE1AT
NOMESCO Finland
Femoral artery PTA
+∞
7.4
7
*
PD3YT
NOMESCO Finland
Pelvic artery PTA with stent
+∞
6.3
6
*
9573
FHL
Leg amputation
+∞
6.3
6
*
PEH57
NOMESCO Finland
Bypass from femoral artery to popliteal artery below knee
+∞
6.3
6
*
PD4AD
NOMESCO Finland
CT of lower extremity arteries
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
General Surgery
2 [38004447]
7.1e-01
1.3e+00
3.3e+00
—
2.0e+00
2.0e+00
1.3e+00
cases:31.82%
controls:18.63%
cases:20.91%
controls:6.94%
cases:13.64%
controls:0.55%
—
—
cases:10.00%
controls:1.46%
cases:31.48%
controls:5.89%
cases:48.08%
controls:20.06%
35
204
75
891
23
76
87
1019
15
6
95
1089
—
11
16
99
1078
34
64
74
1023
50
209
54
833
Outpatient Hospital
22 [8756]
6.7e-01
9.0e-01
2.1e+00
—
2.8e+00
1.6e+00
1.1e+00
cases:30.91%
controls:18.63%
cases:14.55%
controls:6.48%
cases:5.45%
controls:0.73%
—
—
cases:12.73%
controls:0.91%
cases:25.00%
controls:6.26%
cases:45.19%
controls:22.07%
34
204
76
891
16
71
94
1024
6
8
104
1087
—
14
10
96
1084
27
68
81
1019
47
230
57
812
Emergency Room Visit
ER [9203]
2.9e-01
5.9e-01
2.8e+00
—
2.3e+00
1.0e+00
1.1e+00
cases:24.55%
controls:19.63%
cases:14.55%
controls:8.58%
cases:14.55%
controls:1.00%
—
—
cases:8.18%
controls:0.91%
cases:20.37%
controls:8.28%
cases:51.92%
controls:26.58%
27
215
83
880
16
94
94
1001
16
11
94
1084
—
9
10
101
1084
22
90
86
997
54
277
50
765
Rheumatology
66 [38004491]
—
2.1e+00
—
1.0e+50
—
3.2e+00
1.8e+00
—
—
cases:6.36%
controls:0.82%
—
—
cases:9.09%
controls:0.00%
—
—
cases:17.59%
controls:0.83%
cases:13.46%
controls:2.40%
—
7
9
103
1086
—
10
0
100
1095
—
19
9
89
1078
14
25
90
1017
Inpatient Hospital
21 [8717]
4.3e-01
8.5e-01
1.8e+00
—
2.7e+00
1.3e+00
1.1e+00
cases:36.36%
controls:27.03%
cases:20.91%
controls:10.14%
cases:8.18%
controls:1.46%
—
—
cases:18.18%
controls:1.46%
cases:30.56%
controls:10.40%
cases:54.81%
controls:28.50%
40
296
70
799
23
111
87
984
9
16
101
1079
—
20
16
90
1078
33
113
75
974
57
297
47
745
Internal Medicine
11 [38004456]
3.5e-01
6.9e-01
2.4e+00
1.0e+50
2.0e+00
1.3e+00
1.2e+00
cases:22.73%
controls:17.17%
cases:14.55%
controls:7.85%
cases:8.18%
controls:0.82%
cases:16.36%
controls:0.00%
cases:7.27%
controls:1.10%
cases:25.00%
controls:8.37%
cases:44.23%
controls:19.48%
25
188
85
907
16
86
94
1009
9
9
101
1086
18
0
92
1095
8
12
102
1082
27
91
81
996
46
203
58
839
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.1e-01
1.3e+00
—
—
3.0e+00
1.8e+00
1.8e+00
cases:7.27%
controls:4.47%
cases:6.36%
controls:1.74%
—
—
—
—
cases:8.18%
controls:0.46%
cases:11.11%
controls:2.12%
cases:25.96%
controls:5.37%
8
49
102
1046
7
19
103
1076
—
—
9
5
101
1089
12
23
96
1064
27
56
77
986
Outpatient Visit
OP [9202]
3.9e-01
5.5e-01
1.8e+00
—
1.7e+00
1.5e+00
1.1e+00
cases:54.55%
controls:44.75%
cases:42.73%
controls:30.14%
cases:27.27%
controls:5.84%
—
—
cases:30.91%
controls:7.40%
cases:68.52%
controls:32.20%
cases:82.69%
controls:60.65%
60
490
50
605
47
330
63
765
30
64
80
1031
—
34
81
76
1013
74
350
34
737
86
632
18
410
nifedipine; oral, parenteral
C08CA05 [21601751]
1.7e+00
—
—
—
—
3.0e+00
2.7e+00
cases:4.55%
controls:0.82%
—
—
—
—
—
—
—
—
cases:8.33%
controls:0.46%
cases:12.50%
controls:0.96%
5
9
105
1086
—
—
—
—
9
5
99
1082
13
10
91
1032
Pharmacy visit
OMOP4822462 [581458]
1.7e-01
8.0e-01
1.1e+00
2.5e+00
1.1e+00
5.3e-01
2.1e-01
cases:78.18%
controls:75.07%
cases:81.82%
controls:66.85%
cases:56.36%
controls:29.77%
cases:14.55%
controls:1.37%
cases:60.00%
controls:32.27%
cases:79.63%
controls:69.64%
cases:88.46%
controls:86.18%
86
822
24
273
90
732
20
363
62
326
48
769
16
15
94
1080
66
353
44
741
86
757
22
330
92
898
12
144
prednisolone; oral, parenteral
H02AB06 [21602734]
4.3e-01
1.2e+00
2.5e+00
—
—
1.3e+00
9.3e-01
cases:9.09%
controls:6.12%
cases:9.09%
controls:2.92%
cases:5.45%
controls:0.46%
—
—
—
—
cases:11.11%
controls:3.31%
cases:20.19%
controls:9.12%
10
67
100
1028
10
32
100
1063
6
5
104
1090
—
—
12
36
96
1051
21
95
83
947
prednisolone
A07EA01 [21600653]
4.3e-01
1.2e+00
2.5e+00
—
—
1.3e+00
9.3e-01
cases:9.09%
controls:6.12%
cases:9.09%
controls:2.92%
cases:5.45%
controls:0.46%
—
—
—
—
cases:11.11%
controls:3.31%
cases:20.19%
controls:9.12%
10
67
100
1028
10
32
100
1063
6
5
104
1090
—
—
12
36
96
1051
21
95
83
947
Office Visit
OMOP4822458 [581477]
2.8e-01
1.9e+00
—
—
1.0e+50
1.9e+00
9.5e-01
cases:7.27%
controls:5.57%
cases:8.18%
controls:1.28%
—
—
—
—
cases:7.27%
controls:0.00%
cases:9.26%
controls:1.56%
cases:19.23%
controls:8.45%
8
61
102
1034
9
14
101
1081
—
—
8
0
102
1094
10
17
98
1070
20
88
84
954
cefalexin; oral
J01DB01 [21602870]
5.3e-01
1.1e+00
2.0e+00
—
2.4e+00
6.3e-01
1.0e+00
cases:31.82%
controls:21.55%
cases:19.09%
controls:7.49%
cases:4.55%
controls:0.64%
—
—
cases:8.18%
controls:0.82%
cases:12.96%
controls:7.36%
cases:45.19%
controls:22.74%
35
236
75
859
21
82
89
1013
5
7
105
1088
—
9
9
101
1085
14
80
94
1007
47
237
57
805
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.1e-01
5.4e-01
2.1e+00
—
2.2e+00
4.7e-01
1.7e-01
cases:9.09%
controls:6.85%
cases:10.91%
controls:6.67%
cases:7.27%
controls:0.91%
—
—
cases:7.27%
controls:0.82%
cases:11.11%
controls:7.27%
cases:22.12%
controls:19.29%
10
75
100
1020
12
73
98
1022
8
10
102
1085
—
8
9
102
1085
12
79
96
1008
23
201
81
841
methotrexate
L01BA01 [21601423]
—
—
—
—
2.3e+00
2.0e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:5.45%
controls:0.55%
cases:6.48%
controls:0.92%
cases:5.77%
controls:1.73%
—
—
—
—
6
6
104
1088
7
10
101
1077
6
18
98
1024
methotrexate; oral, parenteral
L04AX03 [21603929]
—
—
—
—
2.3e+00
2.0e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:5.45%
controls:0.55%
cases:6.48%
controls:0.92%
cases:5.77%
controls:1.73%
—
—
—
—
6
6
104
1088
7
10
101
1077
6
18
98
1024
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
—
—
2.0e+00
—
2.5e+00
1.6e+00
7.2e-01
—
—
—
—
cases:4.55%
controls:0.64%
—
—
cases:5.45%
controls:0.46%
cases:8.33%
controls:1.84%
cases:11.54%
controls:5.95%
—
—
5
7
105
1088
—
6
5
104
1089
9
20
99
1067
12
62
92
980
Physical Medicine And Rehabilitation
25 [38004468]
1.1e+00
1.6e+00
—
—
—
1.8e+00
1.3e+00
cases:7.27%
controls:2.56%
cases:5.45%
controls:1.19%
—
—
—
—
—
—
cases:6.48%
controls:1.10%
cases:14.42%
controls:4.41%
8
28
102
1067
6
13
104
1082
—
—
—
7
12
101
1075
15
46
89
996
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
7.3e-01
9.3e-01
1.9e+00
—
2.1e+00
9.0e-01
6.3e-01
cases:21.82%
controls:11.87%
cases:17.27%
controls:7.58%
cases:5.45%
controls:0.82%
—
—
cases:8.18%
controls:1.10%
cases:15.74%
controls:7.08%
cases:35.58%
controls:22.65%
24
130
86
965
19
83
91
1012
6
9
104
1086
—
9
12
101
1082
17
77
91
1010
37
236
67
806
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.2e-01
3.6e-01
1.9e+00
—
2.6e+00
1.4e-01
-1.3e-01
cases:7.27%
controls:6.48%
cases:8.18%
controls:5.84%
cases:5.45%
controls:0.82%
—
—
cases:7.27%
controls:0.55%
cases:7.41%
controls:6.53%
cases:16.35%
controls:18.14%
8
71
102
1024
9
64
101
1031
6
9
104
1086
—
8
6
102
1088
8
71
100
1016
17
189
87
853
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.5e-01
3.6e-01
1.9e+00
—
2.6e+00
1.4e-01
-1.2e-01
cases:7.27%
controls:6.30%
cases:8.18%
controls:5.84%
cases:5.45%
controls:0.82%
—
—
cases:7.27%
controls:0.55%
cases:7.41%
controls:6.53%
cases:16.35%
controls:18.04%
8
69
102
1026
9
64
101
1031
6
9
104
1086
—
8
6
102
1088
8
71
100
1016
17
188
87
854
Cardiology
6 [38004451]
3.9e-01
9.9e-01
—
—
—
1.4e+00
1.1e+00
cases:5.45%
controls:3.74%
cases:4.55%
controls:1.74%
—
—
—
—
—
—
cases:11.11%
controls:2.85%
cases:16.35%
controls:5.95%
6
41
104
1054
5
19
105
1076
—
—
—
12
31
96
1056
17
62
87
980
Vascular Surgery
77 [38004496]
2.2e+00
—
1.0e+50
1.0e+50
—
—
2.4e+00
cases:4.55%
controls:0.55%
—
—
cases:9.09%
controls:0.00%
cases:17.27%
controls:0.00%
—
—
—
—
cases:10.58%
controls:1.06%
5
6
105
1089
—
10
0
100
1095
19
0
91
1095
—
—
11
11
93
1031
clopidogrel; oral
B01AC04 [21600989]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.55%
—
—
—
—
—
—
—
6
6
102
1081
—
Laceration/cut
S18 [2002000983]
—
—
—
—
—
2.4e+00
4.0e-01
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.55%
cases:7.69%
controls:5.28%
—
—
—
—
—
6
6
102
1081
8
55
96
987
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.65%
controls:0.96%
—
—
—
—
—
—
9
10
95
1032
pantoprazole; oral, parenteral
A02BC02 [21600097]
7.0e-01
1.1e+00
—
—
1.7e+00
1.3e+00
9.3e-01
cases:10.91%
controls:5.75%
cases:10.91%
controls:3.93%
—
—
—
—
cases:4.55%
controls:0.82%
cases:15.74%
controls:4.78%
cases:23.08%
controls:10.56%
12
63
98
1032
12
43
98
1052
—
—
5
9
105
1085
17
52
91
1035
24
110
80
932
acetylsalicylic acid; oral
B01AC06 [21600991]
—
—
-1.0e+50
—
—
2.1e+00
9.5e-01
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:5.56%
controls:0.74%
cases:4.81%
controls:1.92%
—
—
0
5
110
1090
—
—
6
8
102
1079
5
20
99
1022
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-2.2e-02
4.9e-01
2.1e+00
1.0e+50
—
6.9e-01
3.6e-01
cases:5.45%
controls:5.57%
cases:7.27%
controls:4.57%
cases:5.45%
controls:0.73%
cases:4.55%
controls:0.00%
—
—
cases:9.26%
controls:4.88%
cases:19.23%
controls:14.20%
6
61
104
1034
8
50
102
1045
6
8
104
1087
5
0
105
1095
—
10
53
98
1034
20
148
84
894
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
—
6.7e-01
—
—
—
2.0e+00
5.1e-01
—
—
cases:4.55%
controls:2.37%
—
—
—
—
—
—
cases:10.19%
controls:1.47%
cases:14.42%
controls:9.21%
—
5
26
105
1069
—
—
—
11
16
97
1071
15
96
89
946
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
—
—
—
—
2.0e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:6.48%
controls:0.92%
cases:8.65%
controls:2.50%
—
—
—
—
—
7
10
101
1077
9
26
95
1016
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
—
—
—
—
—
2.0e+00
7.5e-01
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:1.10%
cases:9.62%
controls:4.80%
—
—
—
—
—
8
12
100
1075
10
50
94
992
Monocytes/Leukocytes in Blood
26485-3 [3019069]
—
—
—
—
—
2.0e+00
7.5e-01
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:1.10%
cases:9.62%
controls:4.80%
—
—
—
—
—
8
12
100
1075
10
50
94
992
Basophils/Leukocytes in Blood
30180-4 [3022096]
—
—
—
—
—
2.0e+00
7.3e-01
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:1.10%
cases:9.62%
controls:4.89%
—
—
—
—
—
8
12
100
1075
10
51
94
991
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
—
—
—
—
2.0e+00
8.1e-01
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:1.10%
cases:10.58%
controls:4.99%
—
—
—
—
—
8
12
100
1075
11
52
93
990
hydroxychloroquine; oral
P01BA02 [21604889]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:1.15%
—
—
—
—
—
—
8
12
96
1030
codeine and paracetamol
N02AJ06 [1123647]
7.8e-01
1.9e+00
—
—
—
—
7.4e-01
cases:10.00%
controls:4.84%
cases:10.91%
controls:1.74%
—
—
—
—
—
—
—
—
cases:16.35%
controls:8.54%
11
53
99
1042
12
19
98
1076
—
—
—
—
17
89
87
953
Platelets [#/volume] in Blood
26515-7 [3007461]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
4.0e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.28%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.69%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
14
101
1080
13
91
95
996
23
226
81
816
felodipine; oral
C08CA02 [21601748]
1.2e+00
—
—
—
—
1.9e+00
1.4e+00
cases:4.55%
controls:1.46%
—
—
—
—
—
—
—
—
cases:6.48%
controls:1.01%
cases:6.73%
controls:1.82%
5
16
105
1079
—
—
—
—
7
11
101
1076
7
19
97
1023
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
-1.0e+50
—
—
—
—
1.9e+00
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:7.69%
controls:1.25%
—
0
5
110
1090
—
—
—
—
8
13
96
1029
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
4.0e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.69%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
15
101
1079
13
91
95
996
23
226
81
816
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
4.0e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.69%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
15
101
1079
13
91
95
996
23
226
81
816
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
3.8e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.56%
cases:22.12%
controls:21.69%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
15
101
1079
13
93
95
994
23
226
81
816
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
4.0e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.69%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
15
101
1079
13
91
95
996
23
226
81
816
MCH [Entitic mass]
28539-5 [3035941]
-9.6e-02
4.4e-01
1.5e+00
—
1.9e+00
4.0e-01
2.5e-02
cases:7.27%
controls:7.95%
cases:10.91%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.69%
8
87
102
1008
12
80
98
1015
7
17
103
1078
—
9
15
101
1079
13
91
95
996
23
226
81
816
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-9.6e-02
5.3e-01
1.5e+00
—
1.9e+00
4.0e-01
1.9e-02
cases:7.27%
controls:7.95%
cases:11.82%
controls:7.31%
cases:6.36%
controls:1.55%
—
—
cases:8.18%
controls:1.37%
cases:12.04%
controls:8.37%
cases:22.12%
controls:21.79%
8
87
102
1008
13
80
97
1015
7
17
103
1078
—
9
15
101
1079
13
91
95
996
23
227
81
815
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
—
—
—
—
—
1.8e+00
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:6.48%
controls:1.10%
cases:11.54%
controls:5.09%
—
—
—
—
—
7
12
101
1075
12
53
92
989
General anesthesia, balanced
WX408 [2001310808]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:1.34%
—
—
—
—
—
—
8
14
96
1028
INR in Blood by Coagulation assay
34714-6 [3032080]
—
-1.0e+50
—
—
—
1.7e+00
9.5e-01
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
cases:7.41%
controls:1.38%
cases:11.54%
controls:4.80%
—
0
12
110
1083
—
—
—
8
15
100
1072
12
50
92
992
Laboratory Visit
OMOP4822461 [32036]
1.0e-01
3.2e-01
1.3e+00
1.0e+50
1.6e+00
1.6e-01
-3.9e-02
cases:10.00%
controls:9.13%
cases:12.73%
controls:9.59%
cases:8.18%
controls:2.47%
cases:5.45%
controls:0.00%
cases:9.09%
controls:2.01%
cases:12.96%
controls:11.22%
cases:24.04%
controls:24.76%
11
100
99
995
14
105
96
990
9
27
101
1068
6
0
104
1095
10
22
100
1072
14
122
94
965
25
258
79
784
Neurology
13 [38004458]
-1.4e-01
8.9e-01
—
—
—
1.5e+00
6.7e-01
cases:4.55%
controls:5.21%
cases:4.55%
controls:1.92%
—
—
—
—
—
—
cases:9.26%
controls:2.21%
cases:15.38%
controls:8.54%
5
57
105
1038
5
21
105
1074
—
—
—
10
24
98
1063
16
89
88
953
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:2.50%
—
—
—
—
—
—
10
26
94
1016
lansoprazole; oral
A02BC03 [21600098]
2.3e-01
—
—
—
—
—
1.3e+00
cases:4.55%
controls:3.65%
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:3.65%
5
40
105
1055
—
—
—
—
—
13
38
91
1004
cetirizine; oral
R06AE07 [21603497]
6.9e-01
9.2e-01
—
—
-1.0e+50
9.6e-01
1.2e+00
cases:10.00%
controls:5.30%
cases:7.27%
controls:3.01%
—
—
—
—
cases:0.00%
controls:0.46%
cases:6.48%
controls:2.58%
cases:16.35%
controls:5.57%
11
58
99
1037
8
33
102
1062
—
—
0
5
110
1089
7
28
101
1059
17
58
87
984
furosemide; oral, parenteral
C03CA01 [21601518]
9.9e-01
9.9e-01
—
—
—
1.1e+00
1.2e+00
cases:5.45%
controls:2.10%
cases:5.45%
controls:2.10%
—
—
—
—
—
—
cases:9.26%
controls:3.31%
cases:16.35%
controls:5.76%
6
23
104
1072
6
23
104
1072
—
—
—
10
36
98
1051
17
60
87
982
Inpatient Visit
IP [9201]
1.2e-01
9.9e-01
—
1.0e+50
—
1.3e+00
1.1e+00
cases:10.00%
controls:8.95%
cases:6.36%
controls:2.47%
—
—
cases:17.27%
controls:0.00%
—
—
cases:6.48%
controls:1.93%
cases:14.42%
controls:5.28%
11
98
99
997
7
27
103
1068
—
19
0
91
1095
—
7
21
101
1066
15
55
89
987
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
5.8e-01
—
—
—
—
—
1.1e+00
cases:6.36%
controls:3.65%
—
—
—
—
—
—
—
—
—
—
cases:14.42%
controls:5.57%
7
40
103
1055
—
—
—
—
—
15
58
89
984
Essential (primary) hypertension
I10 [45591453]
—
—
—
1.0e+50
—
1.0e+00
9.1e-01
—
—
—
—
—
—
cases:5.45%
controls:0.00%
—
—
cases:11.11%
controls:4.23%
cases:25.00%
controls:11.80%
—
—
—
6
0
104
1095
—
12
46
96
1041
26
123
78
919
Plantar fascial fibromatosis
M72.2 [45553265]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
budesonide; inhalant
R03BA02 [21603285]
1.1e-01
—
-1.0e+50
—
-1.0e+50
—
-7.9e-02
cases:4.55%
controls:4.11%
—
—
cases:0.00%
controls:0.73%
—
—
cases:0.00%
controls:0.46%
—
—
cases:4.81%
controls:5.18%
5
45
105
1050
—
0
8
110
1087
—
0
5
110
1089
—
5
54
99
988
Health check-up of pregnant person
SPAT1379 [2001700479]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
disulfiram; oral
N07BB01 [21604821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Handing over of treatment supplies
SPAT1262 [2001700363]
-1.0e+50
—
—
—
—
-1.0e+50
6.0e-01
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:4.81%
controls:2.69%
0
9
110
1086
—
—
—
—
0
5
108
1082
5
28
99
1014
Recording of ECG
SPAT1097 [2001700198]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Heart failure
I50 [45581779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Mouth breathing
R06.5 [45573006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Sampling
SPAT1263 [2001700364]
—
—
—
—
—
-1.0e+50
2.3e-02
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:4.81%
controls:4.70%
—
—
—
—
—
0
10
108
1077
5
49
99
993
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
—
beclometasone; inhalant
R03BA01 [21603284]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
cases:0.00%
controls:2.50%
—
0
15
110
1080
—
—
—
0
13
108
1074
0
26
104
1016
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.8e-01
-1.2e-01
—
—
—
-3.3e-01
-7.0e-02
cases:4.55%
controls:5.94%
cases:4.55%
controls:5.11%
—
—
—
—
—
—
cases:4.63%
controls:6.35%
cases:15.38%
controls:16.31%
5
65
105
1030
5
56
105
1039
—
—
—
5
69
103
1018
16
170
88
872
Telehealth
OMOP5556618 [722455]
3.0e-01
—
-1.0e+50
—
-1.0e+50
1.4e-01
5.0e-01
cases:10.00%
controls:7.58%
—
—
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.73%
cases:4.63%
controls:4.05%
cases:20.19%
controls:13.34%
11
83
99
1012
—
0
5
110
1090
—
0
8
110
1086
5
44
103
1043
21
139
83
903
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
—
—
—
—
—
7.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:2.30%
—
—
—
—
—
—
5
24
99
1018
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
7.5e-01
—
—
—
—
—
4.0e-01
cases:6.36%
controls:3.11%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:3.26%
7
34
103
1061
—
—
—
—
—
5
34
99
1008
epitizide and potassium-sparing agents
C03EA03 [21601545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
11
110
1084
0
5
110
1090
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
ticagrelor; oral
B01AC24 [40252640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
hydrocortisone
S02BA01 [21605166]
4.9e-01
—
—
—
—
—
3.3e-01
cases:9.09%
controls:5.75%
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:5.66%
10
63
100
1032
—
—
—
—
—
8
59
96
983
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:5.66%
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
0
62
110
1033
0
17
110
1078
—
—
—
—
—
Fitting and adjustment of hearing aid
Z46.1 [45595518]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
10
110
1085
—
—
—
—
—
0
8
104
1034
Thorax X-ray examination
GD1AA [2001303617]
—
—
—
—
—
—
1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:4.32%
—
—
—
—
—
—
5
45
99
997
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.0e-01
7.5e-01
—
—
2.2e+00
8.1e-01
5.9e-01
cases:4.55%
controls:3.74%
cases:7.27%
controls:3.56%
—
—
—
—
cases:4.55%
controls:0.55%
cases:9.26%
controls:4.32%
cases:18.27%
controls:11.04%
5
41
105
1054
8
39
102
1056
—
—
5
6
105
1088
10
47
98
1040
19
115
85
927
risperidone; oral, parenteral
N05AX08 [21604559]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Laparoscopic cholecystectomy
JKA21 [2001305294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
0
8
110
1087
—
—
—
—
—
0
10
104
1032
Hand/finger symptom/complaint
L12 [2002000636]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
12
104
1030
chloramphenicol
D10AF03 [21602307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
9
110
1086
—
—
—
0
8
108
1079
—
Skin colour change
S08 [2002000973]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
1.6e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:1.01%
cases:8.65%
controls:3.07%
—
—
—
—
—
5
11
103
1076
9
32
95
1010
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Other intraoperative electrophysiological investigation in arhythmia or disturbance of impulse propagation
XFP96 [2001303143]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
0
6
110
1089
—
—
—
—
—
0
5
104
1037
Presence of intraocular lens
Z96.1 [45585885]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
110
1085
—
—
—
—
—
—
Need for immunization against other specified single viral diseases
Z25.8 [45547296]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
11
104
1031
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Upper respiratory infection acute
R74 [2002000942]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
6
110
1089
—
—
—
0
8
108
1079
—
Pneumonia, unspecified
J18.9 [45601123]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
0
10
110
1085
—
—
—
—
0
9
108
1078
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
1.9e-01
9.9e-01
-1.0e+50
—
—
7.6e-01
4.5e-01
cases:5.45%
controls:4.57%
cases:5.45%
controls:2.10%
cases:0.00%
controls:0.82%
—
—
—
—
cases:5.56%
controls:2.67%
cases:9.62%
controls:6.33%
6
50
104
1045
6
23
104
1072
0
9
110
1086
—
—
6
29
102
1058
10
66
94
976
Alzheimer disease with late onset
G30.1 [45552521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:3.93%
—
—
—
—
—
—
7
41
97
1001
dydrogesterone; oral
G03DB01 [21602544]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
108
1082
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
0
15
108
1072
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
-2.8e-01
7.5e-01
—
—
—
2.2e-01
8.2e-02
cases:10.91%
controls:13.97%
cases:8.18%
controls:4.02%
—
—
—
—
—
—
cases:5.56%
controls:4.51%
cases:18.27%
controls:17.08%
12
153
98
942
9
44
101
1051
—
—
—
6
49
102
1038
19
178
85
864
zopiclone; oral
N05CF01 [21604654]
-2.2e-02
—
—
—
—
7.9e-01
3.3e-01
cases:5.45%
controls:5.57%
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.96%
cases:9.62%
controls:7.10%
6
61
104
1034
—
—
—
—
9
43
99
1044
10
74
94
968
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-1.0e+50
—
—
—
—
—
6.8e-01
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:2.50%
0
9
110
1086
—
—
—
—
—
5
26
99
1016
Bacteria identified in Urine by Culture
630-4 [3026008]
—
-1.0e+50
—
—
—
—
1.0e+00
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:5.77%
controls:2.21%
—
0
5
110
1090
—
—
—
—
6
23
98
1019
Laboratory test
15220000 [4034850]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:1.54%
—
—
—
—
—
0
5
108
1082
0
16
104
1026
Assessment of need for oral health care, standard
SAD01 [2001310287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
1.4e+00
—
—
—
—
—
2.9e-01
cases:8.18%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:7.39%
9
24
101
1071
—
—
—
—
—
10
77
94
965
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
-3.8e-01
5.6e-01
—
—
—
6.5e-01
4.5e-02
cases:4.55%
controls:6.48%
cases:6.36%
controls:3.74%
—
—
—
—
—
—
cases:8.33%
controls:4.51%
cases:16.35%
controls:15.74%
5
71
105
1024
7
41
103
1054
—
—
—
9
49
99
1038
17
164
87
878
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
Periodontitis complex
K05.30 [2000502728]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Pain in limb
M79.6 [45587063]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:1.46%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:3.36%
0
16
110
1079
—
—
—
—
—
10
35
94
1007
Headache
R51.80 [2000503603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Fracture of tooth, open
S02.51 [45755762]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
misoprostol; oral, vaginal
G02AD06 [21602443]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
Otolaryngology
4 [38004449]
2.7e-01
—
—
—
—
—
6.8e-01
cases:8.18%
controls:6.39%
—
—
—
—
—
—
—
—
—
—
cases:17.31%
controls:9.60%
9
70
101
1025
—
—
—
—
—
18
100
86
942
chloramphenicol
G01AA05 [21602367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
5.8e-02
—
—
—
—
—
3.7e-01
cases:6.36%
controls:6.03%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:6.81%
7
66
103
1029
—
—
—
—
—
10
71
94
971
furosemide and potassium-sparing agents
C03EB01 [21601554]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
0
7
110
1088
—
—
—
0
9
108
1078
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
eletriptan; oral
N02CC06 [21604381]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
5
110
1090
0
7
110
1088
—
—
—
—
0
8
104
1034
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
0
5
110
1090
—
—
—
—
—
0
15
104
1027
fluconazole; oral, parenteral
J02AC01 [21603080]
2.3e-01
—
—
—
—
—
3.8e-01
cases:6.36%
controls:5.11%
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:4.03%
7
56
103
1039
—
—
—
—
—
6
42
98
1000
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
110
1082
—
—
—
—
—
—
phenylephrine, combinations
R01BA53 [21603214]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
0
10
110
1085
—
—
—
0
10
108
1077
—
metformin and sitagliptin
A10BD07 [21600772]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Health maint/preventive medicine
A98 [2002000231]
-2.3e-01
-5.8e-02
—
—
-1.0e+50
-2.5e-02
7.8e-03
cases:8.18%
controls:10.05%
cases:7.27%
controls:7.67%
—
—
—
—
cases:0.00%
controls:1.19%
cases:9.26%
controls:9.48%
cases:24.04%
controls:23.90%
9
110
101
985
8
84
102
1011
—
—
0
13
110
1081
10
103
98
984
25
249
79
793
antibiotics in combination with other drugs
S01AA20 [21603571]
6.0e-02
—
—
—
—
—
9.8e-02
cases:4.55%
controls:4.29%
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:6.14%
5
47
105
1048
—
—
—
—
—
7
64
97
978
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
14
110
1081
0
8
110
1087
—
—
—
0
7
108
1080
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
—
-1.0e+50
—
—
—
—
1.0e+00
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:6.73%
controls:2.50%
—
0
5
110
1090
—
—
—
—
7
26
97
1016
Telephone prescription or other care instructions
WZB00 [2001310884]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
Melaena
K92.1 [45533624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Left side
ZXA05 [2001311347]
1.2e+00
-1.0e+50
—
—
—
—
9.1e-01
cases:4.55%
controls:1.37%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:5.77%
controls:2.40%
5
15
105
1080
0
5
110
1090
—
—
—
—
6
25
98
1017
chloramphenicol; ointment
D06AX02 [21602063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
110
1084
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
opium derivatives and expectorants
R05FA02 [21603439]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
9
110
1086
—
—
—
0
8
108
1079
—
Lump/swelling localized
S04 [2002000969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
betamethasone
A07EA04 [21600656]
6.6e-01
—
—
—
—
—
8.1e-01
cases:8.18%
controls:4.38%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.51%
9
48
101
1047
—
—
—
—
—
10
47
94
995
Dyspnoea
R06.0 [45558449]
-1.0e+50
—
—
—
—
—
1.6e+00
cases:0.00%
controls:1.74%
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:1.44%
0
19
110
1076
—
—
—
—
—
7
15
97
1027
Body mass index
60621009 [4245997]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:0.00%
—
—
—
—
—
—
10
0
94
1042
Orthostatic test
SPAT1101 [2001700202]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
mirtazapine; oral
N06AX11 [21604740]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:4.13%
—
—
—
—
—
—
8
43
96
999
Caries limited to enamel
K02.0 [45576967]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Emergency Room and Inpatient Visit
ERIP [262]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
Approximal wear
K03.00 [2000502665]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Subjective visual disturbances
H53.1 [45557467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Rotator cuff syndrome
M75.1 [45596678]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
brompheniramine, combinations
R06AB51 [21603466]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
0
10
110
1085
—
—
—
0
10
108
1077
—
clarithromycin; oral, parenteral
J01FA09 [21602977]
5.2e-01
—
—
—
—
-1.0e+50
5.0e-01
cases:4.55%
controls:2.74%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:4.81%
controls:2.98%
5
30
105
1065
—
—
—
—
0
9
108
1078
5
31
99
1011
timolol, combinations
S01ED51 [21603705]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.67%
0
9
110
1086
—
—
—
—
0
5
108
1082
0
7
104
1035
Case Management Agency
251B00000X [38004193]
-1.8e-03
1.8e-01
7.7e-01
—
9.4e-01
1.9e-01
-1.2e-01
cases:28.18%
controls:28.22%
cases:26.36%
controls:23.01%
cases:12.73%
controls:6.30%
—
—
cases:14.55%
controls:6.22%
cases:31.48%
controls:27.60%
cases:49.04%
controls:52.11%
31
309
79
786
29
252
81
843
14
69
96
1026
—
16
68
94
1026
34
300
74
787
51
543
53
499
Hip symptom/complaint
L13 [2002000637]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
0
13
104
1029
fenoterol and ipratropium bromide
R03AL01 [43534843]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
0
8
110
1087
—
—
—
0
10
108
1077
—
Medical Oncology
90 [38004507]
—
—
—
—
—
—
5.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:2.88%
—
—
—
—
—
—
5
30
99
1012
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
-3.6e-01
8.1e-01
—
—
—
8.7e-01
2.2e-01
cases:4.55%
controls:6.39%
cases:6.36%
controls:2.92%
—
—
—
—
—
—
cases:8.33%
controls:3.68%
cases:16.35%
controls:13.53%
5
70
105
1025
7
32
103
1063
—
—
—
9
40
99
1047
17
141
87
901
Pulp capping
SGC10 [2001310393]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
6.5e-01
—
—
—
—
—
-1.4e-01
cases:10.00%
controls:5.48%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:5.47%
11
60
99
1035
—
—
—
—
—
5
57
99
985
amitriptyline and psycholeptics
N06CA01 [21604789]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
11
104
1031
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
1.1e+00
-1.0e+50
—
—
—
—
5.0e-01
cases:8.18%
controls:2.92%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:4.81%
controls:2.98%
9
32
101
1063
0
9
110
1086
—
—
—
—
5
31
99
1011
Depressive disorder
P76 [2002000870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
metoprolol and felodipine
C07FB02 [21601742]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.58%
—
—
—
—
—
0
5
108
1082
0
6
104
1036
Nonallergic asthma
J45.1 [45557625]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
9
110
1086
—
—
—
—
0
5
108
1082
—
nystatin; vaginal
G01AA01 [21602363]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
oxazepam; oral
N05BA04 [21604569]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:4.13%
—
—
—
—
—
—
7
43
97
999
Injection therapy, other than intramuscular or subcutaneous
SPAT1203 [2001700304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Other hammer toe(s) (acquired)
M20.4 [45562664]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Assessment of need for aid
SPAT1229 [2001700330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
aciclovir; oral, parenteral
J05AB01 [21603131]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
0
7
108
1080
—
moxonidine; oral
C02AC05 [21600401]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.86%
—
0
6
110
1089
—
—
—
0
7
108
1080
0
9
104
1033
Bradycardia, unspecified
R00.1 [45539313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
bisoprolol; oral
C07AB07 [21601689]
2.5e-01
4.0e-01
—
—
—
2.6e-01
1.2e-01
cases:10.00%
controls:7.95%
cases:10.00%
controls:6.94%
—
—
—
—
—
—
cases:9.26%
controls:7.27%
cases:14.42%
controls:12.96%
11
87
99
1008
11
76
99
1019
—
—
—
10
79
98
1008
15
135
89
907
Risk factor NOS
A23 [2002000158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Constipation
K59.0 [45557663]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
—
—
—
—
—
1.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:4.13%
—
—
—
—
—
—
5
43
99
999
Monitoring the use of the aid
R5140 [2001310249]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
—
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Type 2 diabetes mellitus, with ophthalmic complications
E11.3 [45591028]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Transient cerebral ischaemic attack, unspecified
G45.9 [45542892]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
0
7
110
1088
—
—
—
—
—
0
11
104
1031
fluticasone furoate; nasal
R01AD12 [21605053]
4.1e-01
—
—
—
—
—
1.6e-02
cases:7.27%
controls:4.93%
—
—
—
—
—
—
—
—
—
—
cases:7.69%
controls:7.58%
8
54
102
1041
—
—
—
—
—
8
79
96
963
metoprolol; oral, parenteral
C07AB02 [21601684]
2.7e-01
2.5e-01
—
—
—
-1.1e-01
-2.6e-01
cases:6.36%
controls:4.93%
cases:5.45%
controls:4.29%
—
—
—
—
—
—
cases:4.63%
controls:5.15%
cases:4.81%
controls:6.14%
7
54
103
1041
6
47
104
1048
—
—
—
5
56
103
1031
5
64
99
978
Urology
34 [38004474]
4.3e-01
—
-1.0e+50
—
—
—
3.5e-01
cases:4.55%
controls:3.01%
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:7.69%
controls:5.57%
5
33
105
1062
—
0
7
110
1088
—
—
—
8
58
96
984
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
—
—
—
—
2.2e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:0.55%
cases:7.69%
controls:2.02%
—
—
—
—
—
5
6
103
1081
8
21
96
1021
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:2.02%
—
—
—
—
—
—
6
21
98
1021
donepezil; oral
N06DA02 [21604795]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
5
110
1090
—
—
—
—
—
0
8
104
1034
clindamycin; vaginal
G01AA10 [21602372]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
18
110
1077
—
—
—
—
0
7
108
1080
—
insulin (human); parenteral
A10AB01 [21600715]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.83%
cases:0.00%
controls:1.46%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
0
20
110
1075
0
16
110
1079
0
6
110
1089
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
12
104
1030
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
-1.0e+50
—
—
—
—
4.2e-01
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
cases:6.73%
controls:4.51%
—
0
15
110
1080
—
—
—
—
7
47
97
995
Shoulder symptom/complaint
L08 [2002000632]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
13
110
1082
—
—
—
—
0
5
108
1082
—
Electrocardiogram with exercise test
46136006 [4261794]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:2.40%
—
—
—
—
—
—
6
25
98
1017
diclofenac, combinations; oral
M01AB55 [21603959]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
0
15
104
1027
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
Unstable angina
I20.00 [2000502384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Fall on and from stairs and steps
W10 [45756250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Chronic obstructive pulmonary disease, unspecified
J44.9 [45548115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:1.06%
—
—
—
—
—
0
6
108
1081
0
11
104
1031
latanoprost
S01EE01 [21603710]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
5
110
1090
—
—
—
—
—
0
6
104
1036
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
9
110
1086
—
—
—
0
8
108
1079
—
nortriptyline; oral, parenteral
N06AA10 [21604697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Systemic sclerosis, unspecified
M34.9 [45533828]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:0.00%
—
—
—
—
—
—
—
5
0
103
1087
—
Upper gastrointestinal surgery
106 [44777669]
—
—
—
—
—
1.3e+00
7.1e-01
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:1.56%
cases:13.46%
controls:7.10%
—
—
—
—
—
6
17
102
1070
14
74
90
968
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
—
-1.0e+50
—
—
—
—
3.8e-01
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
cases:5.77%
controls:4.03%
—
0
12
110
1083
—
—
—
—
6
42
98
1000
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
—
—
—
—
—
1.5e+00
9.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:1.29%
cases:13.46%
controls:5.57%
—
—
—
—
—
6
14
102
1073
14
58
90
984
tamsulosin and dutasteride
G04CA52 [21602673]
-1.0e+50
—
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:0.00%
controls:0.55%
—
—
0
5
110
1090
—
0
5
110
1090
—
—
0
6
108
1081
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
hydrocortisone aceponate
D07AC16 [21602135]
4.0e-01
1.2e+00
—
—
—
—
2.9e-01
cases:9.09%
controls:6.30%
cases:4.55%
controls:1.37%
—
—
—
—
—
—
—
—
cases:8.65%
controls:6.62%
10
69
100
1026
5
15
105
1080
—
—
—
—
9
69
95
973
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:3.55%
—
—
—
—
—
—
6
37
98
1005
Angina pectoris, unspecified
I20.90 [2000502402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1086
—
—
—
—
—
—
Endocrinology
46 [38004485]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
13
108
1074
—
Raynaud syndrome
I73.0 [45533498]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:0.00%
—
—
—
—
—
—
—
5
0
103
1087
—
Pelvis X-ray examination
NE1AA [2001307792]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Monitoring of emergency patient
SPAT1104 [2001700205]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.96%
0
11
110
1084
0
7
110
1088
—
—
—
0
5
108
1082
0
10
104
1032
lercanidipine; oral
C08CA13 [21601759]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
0
6
110
1088
—
—
Screening procedure
SPAT1324 [2001700425]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
110
1083
—
—
—
—
—
—
carisoprodol; oral
M03BA02 [21604094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:1.73%
—
—
—
—
—
—
5
18
99
1024
warfarin; oral, parenteral
B01AA03 [21600965]
—
—
—
—
—
7.9e-01
9.4e-01
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:3.50%
cases:12.50%
controls:5.28%
—
—
—
—
—
8
38
100
1049
13
55
91
987
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
7.0e-01
4.6e-01
—
—
—
1.0e+00
5.1e-01
cases:9.09%
controls:4.75%
cases:4.55%
controls:2.92%
—
—
—
—
—
—
cases:7.41%
controls:2.76%
cases:10.58%
controls:6.62%
10
52
100
1043
5
32
105
1063
—
—
—
8
30
100
1057
11
69
93
973
tamsulosin; oral
G04CA02 [21602669]
—
8.2e-01
—
—
-1.0e+50
—
7.9e-01
—
—
cases:5.45%
controls:2.47%
—
—
—
—
cases:0.00%
controls:0.82%
—
—
cases:9.62%
controls:4.61%
—
6
27
104
1068
—
—
0
9
110
1085
—
10
48
94
994
Risk factor cardiovascular disease
K22 [2002000551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
norethisterone and ethinylestradiol
G03AA05 [21602478]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:1.25%
—
—
—
—
—
—
5
13
99
1029
Small restoration
SFA00 [2001310357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Malaise and fatigue
R53 [45553741]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
—
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
0
6
110
1089
—
—
—
—
—
0
5
104
1037
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1087
—
—
—
—
—
Memory disturbance
P20 [2002000816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
enalapril and diuretics
C09BA02 [21601804]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
0
5
110
1089
—
—
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
9.4e-01
—
—
—
—
—
7.9e-01
cases:9.09%
controls:3.74%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.61%
10
41
100
1054
—
—
—
—
—
10
48
94
994
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Fusion of first tarsometatarsal joint
NHG80 [2001308322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Abdominal pain/cramps general
D01 [2002000300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
methylprednisolone; oral, parenteral
H02AB04 [21602732]
9.4e-01
2.2e+00
—
—
—
—
1.1e+00
cases:4.55%
controls:1.83%
cases:4.55%
controls:0.55%
—
—
—
—
—
—
—
—
cases:4.81%
controls:1.73%
5
20
105
1075
5
6
105
1089
—
—
—
—
5
18
99
1024
Thoracic Surgery (Cardiothoracic Vascular Surgery) Physician
208G00000X [38004023]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:6.36%
controls:0.00%
—
—
—
—
—
—
—
—
—
7
0
103
1095
—
—
—
cyproterone and estrogen
G03HB01 [21602617]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
8
110
1087
0
5
110
1090
—
—
—
0
7
108
1080
—
ibuprofen
R02AX02 [1588667]
-5.7e-03
7.0e-01
—
—
1.6e+00
8.4e-01
2.4e-01
cases:20.00%
controls:20.09%
cases:17.27%
controls:9.41%
—
—
—
—
cases:6.36%
controls:1.37%
cases:17.59%
controls:8.46%
cases:32.69%
controls:27.64%
22
220
88
875
19
103
91
992
—
—
7
15
103
1079
19
92
89
995
34
288
70
754
General health counselling
SPAT1312 [2001700413]
—
—
—
—
—
—
5.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:3.84%
—
—
—
—
—
—
7
40
97
1002
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
Remowal of suture of skin
TQW40 [2001310146]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Tachycardia, unspecified
R00.0 [45606790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1090
—
—
—
—
—
—
Urine symptom/complaint other
U07 [2002001142]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1088
—
—
—
—
—
—
More than one and less than three hours
ZXE10 [2001311401]
8.8e-01
—
—
—
—
—
8.6e-01
cases:6.36%
controls:2.74%
—
—
—
—
—
—
—
—
—
—
cases:8.65%
controls:3.84%
7
30
103
1065
—
—
—
—
—
9
40
95
1002
carbamazepine; oral, rectal
N03AF01 [21604417]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:1.44%
—
0
6
110
1089
—
—
—
0
7
108
1080
0
15
104
1027
Lower uterine segment caesarean section
MCA10 [2001306959]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
4.8e-01
-1.0e+50
—
—
—
—
4.7e-01
cases:9.09%
controls:5.84%
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
cases:6.73%
controls:4.32%
10
64
100
1031
0
14
110
1081
—
—
—
—
7
45
97
997
Other spondylosis, multiple sites in spine
M47.80 [42617655]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Polyuria
R35 [45539331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.2e+00
—
—
—
—
—
6.7e-01
cases:6.36%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:3.55%
7
21
103
1074
—
—
—
—
—
7
37
97
1005
podophyllotoxin
D06BB04 [21602086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
Periodontal treatment
SDA03 [2001310328]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1086
—
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
chloramphenicol
S02AA01 [21605147]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.86%
—
—
—
—
—
—
5
9
99
1033
salbutamol; inhalant
R03AC02 [21603256]
4.8e-01
2.5e-01
—
—
—
7.2e-01
6.7e-01
cases:10.91%
controls:7.03%
cases:5.45%
controls:4.29%
—
—
—
—
—
—
cases:8.33%
controls:4.23%
cases:18.27%
controls:10.27%
12
77
98
1018
6
47
104
1048
—
—
—
9
46
99
1041
19
107
85
935
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
—
—
—
—
—
—
6.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.58%
controls:5.66%
—
—
—
—
—
—
11
59
93
983
More than three and less than five hours
ZXE20 [2001311408]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.77%
—
—
—
—
—
—
5
8
99
1034
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
0
18
110
1077
0
8
110
1087
—
—
—
—
—
Ankle symptom/complaint
L16 [2002000640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
tibolone; oral
G03CX01 [21602536]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
verapamil; oral, parenteral
C08DA01 [21601767]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.77%
0
8
110
1087
0
7
110
1088
—
—
—
0
7
108
1080
0
8
104
1034
nystatin
D01AA01 [21601911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
7
104
1035
Hip X-ray examination
NF1AA [2001307894]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
2.5e-01
—
—
—
—
—
3.4e-01
cases:12.73%
controls:10.23%
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:11.42%
14
112
96
983
—
—
—
—
—
16
119
88
923
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
0
12
110
1083
—
—
—
—
0
9
108
1078
—
Other specified counselling
Z71.8 [45581061]
-1.0e+50
—
—
—
—
—
1.2e+00
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:1.54%
0
10
110
1085
—
—
—
—
—
5
16
99
1026
Body height measure
50373000 [4177340]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:0.00%
—
—
—
—
—
—
10
0
94
1042
Other allergic rhinitis
J30.3 [45538477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
104
1037
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
—
—
—
—
—
1.2e+00
7.9e-01
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:1.38%
cases:10.58%
controls:5.09%
—
—
—
—
—
5
15
103
1072
11
53
93
989
budesonide; nasal
R01AD05 [21605047]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
0
7
110
1088
—
—
—
—
—
0
7
104
1035
prednisone
A07EA03 [21600655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
110
1079
—
—
—
—
—
—
betahistine; oral
N07CA01 [21604833]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
5
110
1090
—
—
—
0
5
108
1082
—
salmeterol and fluticasone
R03AK06 [21603280]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
0
16
110
1079
—
—
0
7
110
1087
—
—
Fracture of lateral malleolus
S82.6 [45569819]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
6
104
1036
Asthma
J45 [45596282]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
0
8
108
1079
—
Acute bronchitis
J20 [45581849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1089
—
—
—
—
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
7.5e-01
—
—
—
—
—
—
cases:4.55%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
105
1071
—
—
—
—
—
—
Retention of urine
R33 [45587507]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
108
1082
—
ketorolac
S01BC05 [21603643]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
8
104
1034
alendronic acid; oral
M05BA04 [21604152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1086
—
—
—
—
—
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
—
—
—
-1.0e+50
—
7.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
cases:8.65%
controls:4.51%
—
—
—
—
0
6
110
1088
—
9
47
95
995

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
149
2.50
4.48
2.3
2.1
—
—
—
0
0
55
329
2.13
4.26
4.7
4.1
—
—
—
0
0
36
204
2.04
3.10
5.9
3.6
314.96
85.07
ng/l
0.47
27
167
75
549
1.82
2.92
23.8
16.3
1.41
1.32
inr
0.62
67
452
56
377
1.83
2.86
12.2
5.0
—
—
—
0
0
52
346
1.81
2.74
3.5
2.3
—
—
—
0
0
65
470
1.73
2.54
3.8
2.9
—
—
estimate
—
0
0
21
108
2.12
2.31
3.2
1.6
—
—
—
0
0
75
576
1.67
2.26
8.1
7.2
1.20
1.20
mmol/l
0.09
63
493
5
9
5.72
2.23
1.6
1.1
—
—
—
0
0
5
10
5.14
2.09
2.8
2.1
—
—
—
0
0
44
299
1.70
2.08
2.7
2.1
5.50
2.87
mg/l
1.65
39
252
52
370
1.66
2.06
4.8
3.1
49.76
252.47
e6/l
0.58
43
277
6
15
4.13
2.06
1.2
1.1
—
—
—
0
0
24
136
1.93
2.04
1.7
1.3
1520.00
381.71
titre
—
10
35
47
328
1.66
2.00
4.1
3.7
0.00
0.00
estimate
-0.00
18
106
18
93
2.08
1.96
8.6
8.1
—
—
—
0
0
5
11
4.67
1.96
1.6
1.2
—
—
—
0
0
5
11
4.67
1.96
1.6
1.1
—
—
—
0
0
57
421
1.61
1.93
6.1
3.7
839.31
82.62
e6/l
0.48
44
297
20
110
1.96
1.85
3.1
3.8
2.95
2.13
mmol/l
0.30
15
89
5
12
4.28
1.84
1.6
1.4
—
—
—
0
0
6
18
3.44
1.76
2.2
1.5
21.08
15.62
ug/l
—
6
18
20
112
1.92
1.76
3.3
4.0
7.37
7.39
ph
0.70
14
67
18
98
1.96
1.71
1.6
3.0
64.48
66.87
g/l
0.63
18
88
20
115
1.87
1.63
3.3
3.8
5.93
5.70
kpa
0.27
20
108
5
14
3.66
1.63
1.8
1.4
1.82
1.39
mmol/l
—
5
14
18
100
1.92
1.62
5.9
4.0
1.00
0.86
%
—
9
35
71
568
1.52
1.62
4.5
3.8
0.00
0.00
estimate
-0.00
20
120
17
93
1.95
1.60
6.5
3.9
0.50
0.38
%
—
8
29
71
570
1.51
1.58
10.8
5.5
1.59
1.81
e9/l
1.21
64
502
60
465
1.52
1.58
3.8
3.5
6.03
6.20
ph
0.90
38
264
72
580
1.51
1.58
4.7
3.8
0.00
2.69
estimate
0.50
19
113
43
312
1.55
1.51
4.8
3.0
1.11
0.32
e6/l
0.37
34
225
12
59
2.13
1.48
5.5
2.9
—
—
—
0
0
71
576
1.49
1.47
4.7
3.8
0.00
0.00
estimate
-0.00
19
124
32
219
1.60
1.44
4.5
2.9
504.52
534.74
mosm/kgh2o
0.35
32
188
24
153
1.69
1.41
9.1
9.0
5.15
5.20
kpa
0.07
24
147
24
153
1.69
1.41
9.1
9.1
10.26
11.79
kpa
1.21
24
147
81
933
0.67
1.40
5.2
5.2
2.01
1.94
mu/l
0.14
73
843
44
327
1.51
1.38
4.4
3.4
0.00
0.33
estimate
0.65
15
93
5
17
3.01
1.37
1.4
1.8
—
—
—
0
0
30
419
0.64
1.37
2.2
1.9
1.22
1.31
mmol/l
0.44
24
337
46
346
1.50
1.36
4.8
4.1
7.40
7.40
ph
0.04
37
245
19
116
1.74
1.30
2.5
2.7
77.87
64.90
e9/l
0.86
13
86
22
141
1.67
1.27
7.8
6.1
1.03
1.03
mmol/l
0.00
22
130
70
578
1.43
1.26
8.5
6.8
10.60
12.37
umol/l
1.05
70
553
68
561
1.42
1.22
10.9
5.4
0.66
0.61
e9/l
0.69
61
479
86
970
0.69
1.22
7.0
6.6
40.25
39.39
mmol/mol
0.42
79
899
44
335
1.46
1.21
3.4
3.0
—
—
—
0
0
16
95
1.78
1.20
6.5
4.1
0.00
0.13
%
—
7
30
13
72
1.89
1.20
10.0
6.5
24.42
24.89
mmol/l
0.12
13
72
25
169
1.59
1.18
4.7
2.9
1.27
1.47
e6/l
0.11
15
86
68
564
1.41
1.17
11.4
5.4
0.05
0.04
e9/l
0.98
61
482
15
88
1.79
1.17
5.8
9.1
—
—
—
0
0
5
20
2.55
1.16
3.2
2.5
9.68
8.29
kpa
—
5
20
5
20
2.55
1.16
3.2
2.5
4.90
4.79
kpa
—
5
20
23
153
1.61
1.16
9.4
9.1
7.41
7.42
ph
0.05
14
98
5
21
2.43
1.10
4.6
3.2
—
—
—
0
0
22
147
1.59
1.09
1.2
1.3
—
—
—
0
0
14
83
1.77
1.06
5.7
3.3
—
—
—
0
0
90
998
0.71
1.05
5.0
5.5
5.95
5.93
mmol/l
0.07
82
909
69
585
1.36
1.00
12.3
5.8
0.18
0.20
e9/l
0.37
61
502
14
87
1.68
0.91
4.3
2.0
8.97
10.55
g/l
0.82
14
80
15
96
1.63
0.89
1.5
1.5
—
—
—
0
0
15
96
1.63
0.89
7.6
4.3
0.17
0.31
%
—
6
29
32
244
1.41
0.86
6.3
4.5
—
—
—
0
0
13
81
1.67
0.85
1.2
2.9
—
—
—
0
0
6
32
1.91
0.83
1.0
1.1
—
—
—
0
0
8
47
1.75
0.82
2.5
3.1
—
—
—
0
0
0
24
0.00
0.80
0.0
1.1
—
—
—
0
0
57
483
1.31
0.78
5.7
4.0
40.53
47.68
ng/l
0.23
47
378
11
67
1.70
0.78
2.4
2.6
1.46
1.29
%
0.30
11
67
5
23
2.22
0.77
1.6
1.7
31.80
32.43
pg
—
5
23
37
295
1.35
0.77
9.4
6.2
—
—
—
0
0
72
633
1.29
0.74
13.6
9.7
5.28
4.19
e9/l
1.82
65
548
33
261
1.35
0.72
6.3
3.7
83.82
85.98
%
0.15
33
256
26
199
1.38
0.69
4.0
3.3
0.77
0.81
mmol/l
1.12
26
190
5
27
1.88
0.69
3.2
2.7
7.36
7.42
ph
—
5
27
32
255
1.33
0.66
1.5
1.3
—
—
—
0
0
53
454
1.27
0.65
19.9
11.8
0.00
0.01
e9/l
0.26
45
368
60
523
1.26
0.64
7.7
6.5
1.20
1.21
mmol/l
0.75
55
474
5
30
1.69
0.62
1.2
1.2
—
—
—
0
0
30
242
1.31
0.58
1.8
1.9
388.50
460.30
pmol/l
0.50
22
204
12
82
1.51
0.56
11.0
8.1
93.01
94.20
%
0.42
12
82
10
66
1.56
0.54
2.0
2.6
0.64
0.63
%
—
10
66
70
769
0.82
0.53
3.7
4.2
15.46
14.95
pmol/l
0.80
62
695
19
145
1.36
0.52
2.1
4.9
2.98
40.06
ug/l
0.72
19
124
51
446
1.23
0.51
4.7
3.8
0.00
0.05
estimate
0.78
18
100
17
128
1.38
0.50
2.2
1.6
—
—
—
0
0
7
46
1.55
0.49
4.7
14.6
0.64
0.88
%
—
7
41
96
1018
0.81
0.49
5.7
6.0
2.42
2.58
mmol/l
0.85
89
930
97
1026
0.81
0.47
27.9
15.4
—
—
—
0
0
8
56
1.45
0.43
3.6
12.2
1.38
1.60
%
—
8
51
13
96
1.39
0.43
1.8
1.4
—
—
—
0
0
94
993
0.83
0.42
5.4
5.3
4.23
4.47
mmol/l
1.32
87
910
0
16
0.00
0.41
0.0
1.1
—
0.18
—
0
8
0
17
0.00
0.41
0.0
1.1
—
5.60
—
0
11
54
487
1.18
0.38
3.8
2.9
109.72
123.77
ug/l
0.21
49
447
6
43
1.41
0.35
1.2
1.2
—
—
—
0
0
39
344
1.19
0.35
2.3
1.8
16.54
21.37
nmol/l
1.04
30
282
94
987
0.85
0.35
5.2
5.3
1.35
1.45
mmol/l
1.35
86
898
25
213
1.21
0.32
2.0
1.8
1086.08
1202.11
nmol/l
0.29
19
162
20
233
0.83
0.26
1.3
1.2
0.30
2.07
u/ml
—
5
60
40
439
0.87
0.25
2.1
2.2
—
—
—
0
0
33
367
0.87
0.25
3.6
3.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
2.38
—
0
5
0
10
0.00
0.21
0.0
1.0
—
2.64
—
0
5
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
41
377
1.13
0.21
4.6
3.8
16.39
7.33
mg/mmol
0.63
28
231
0
13
0.00
0.21
0.0
1.0
—
2.24
—
0
8
92
953
0.89
0.20
4.6
4.5
1.26
1.22
mmol/l
0.23
85
863
19
217
0.86
0.20
1.5
1.4
1.91
2.54
g/l
1.09
14
117
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
5
70
0.70
0.17
1.2
1.4
—
—
—
0
0
18
159
1.15
0.16
1.6
1.6
—
—
—
0
0
6
79
0.75
0.16
1.2
1.2
—
—
—
0
0
13
112
1.18
0.15
1.3
1.4
—
—
—
0
0
7
90
0.77
0.15
3.3
1.9
5.50
6.15
ph
—
7
57
39
414
0.92
0.13
7.2
3.8
—
—
—
0
0
46
482
0.93
0.11
4.4
5.6
2.52
3.15
ug/l
0.29
40
420
6
58
1.04
0.08
1.0
1.2
—
—
—
0
0
14
127
1.11
0.08
1.4
1.4
—
—
—
0
0
48
496
0.95
0.07
2.7
2.2
96.79
96.90
pmol/l
0.00
34
255
12
110
1.10
0.05
1.2
1.5
—
—
—
0
0
81
797
1.04
0.05
36.4
21.8
14.82
13.81
%
3.22
81
789
37
359
1.04
0.04
4.1
3.2
41.66
47.72
mg/l
0.17
24
231
16
156
1.03
0.00
1.4
1.3
—
—
—
0
0
18
181
0.99
0.00
1.3
1.3
15.98
35.15
iu/ml
—
5
55
28
279
1.00
0.00
2.5
3.3
0.93
0.81
ug/l
0.21
18
198
5
56
0.89
0.00
1.2
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
261.00
—
0
8
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
1.36
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
6
62
0.97
-0.00
4.7
3.7
37.00
36.87
°c
—
6
62
0
5
0.00
-0.00
0.0
1.4
—
197.96
—
0
5
16
160
1.00
-0.00
1.3
1.4
25.78
6.10
u/ml
—
6
49
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
43.71
—
0
7
0
5
0.00
-0.00
0.0
2.0
—
1800.00
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint I9_THROMBANG and mortality.

Females

Parameter HR [95% CI] p-value
I9_THROMBANG 2.288 [1.72, 3.04] < 0.001
Birth year 0.996 [0.99, 1.0] 0.357

During the follow-up period (1.1.1998 — 31.12.2019), 81 out of 256 females with I9_THROMBANG died.

Males

Parameter HR [95% CI] p-value
I9_THROMBANG 1.982 [1.58, 2.48] < 0.001
Birth year 0.986 [0.98, 1.0] 0.004

During the follow-up period (1.1.1998 — 31.12.2019), 146 out of 390 males with I9_THROMBANG died.

Mortality risk

Mortality risk for people of age

years, who have I9_THROMBANG.

N-year risk Females Males
1 0.265% 0.289%
5 1.479% 2.21%
10 3.389% 5.427%
15 6.828% 9.841%
20 11.912% 16.326%

Relationships between endpoints

↥

Index endpoint: I9_THROMBANG – Thromboangiitis obliterans

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data